BioCentury | Nov 4, 2013
Clinical News

AST-120: Development discontinued

...was in Phase III testing. Mitsubishi has global rights to develop AST-120 for CKD from Kureha...
...from Kureha for liver and gastrointestinal diseases. Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508), Osaka, Japan Kureha Corp....
BioCentury | Oct 15, 2012
Clinical News

Kremezin: Phase III data

...initiation of dialysis, kidney transplantation or doubling of serum creatinine levels vs. placebo. Mitsubishi and Kureha...
...in San Diego in November. Mitsubishi has global rights to develop AST-120 for CKD from Kureha...
...from Kureha for liver and gastrointestinal diseases. Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508), Osaka, Japan Kureha Corp....
BioCentury | May 28, 2012
Clinical News

Zysa regulatory update

...where the product is in Phase II testing for non-constipating IBS. Ocera licensed Zysa from Kureha Corp....
BioCentury | May 10, 2010
Clinical News

AST-120: Phase II data

...were presented at the Digestive Disease Week meeting in New Orleans. Ocera licensed AST-120 from Kureha Corp....
BioCentury | Mar 1, 2010
Regulation

As good as it gets

...not currently enough to get approved," he said. Ocera licensed ex-Asian rights to AST-120 from Kureha Corp....
...Osaka:4568), Tokyo, Japan Harvard Medical School , Cambridge, Mass. Johns Hopkins University , Baltimore, Md. Kureha Corp....
BioCentury | Mar 1, 2010
Clinical News

AST-120: Completed Phase IIb enrollment

...grams oral AST-120 given thrice daily for up to 8 weeks. Ocera licensed AST-120 from Kureha Corp....
BioCentury | May 4, 2009
Clinical News

AST-120: Phase IIb started

...three times daily for 8 weeks in up to 150 patients. Ocera licensed AST-120 from Kureha Corp....
BioCentury | Feb 25, 2008
Finance

Ebb & Flow

...rights to AST-120 to treat GI and liver diseases. The candidate was from Japanese company Kureha...
...and Korea. In May 2006, Ocera released Phase III data from a trial run by Kureha...
BioCentury | Feb 21, 2008
Financial News

Ocera raises $35.5 million

...Ocera in-licensed the oral nanoporous microsphere agent, which absorbs toxins from the gastrointestinal tract, from Kureha...
BioCentury | Jan 14, 2008
Clinical News

AST-120 regulatory update

...tract, is in a Phase II trial to treat active pouchitis. Ocera licensed AST-120 from Kureha Corp....
Items per page:
1 - 10 of 19
BioCentury | Nov 4, 2013
Clinical News

AST-120: Development discontinued

...was in Phase III testing. Mitsubishi has global rights to develop AST-120 for CKD from Kureha...
...from Kureha for liver and gastrointestinal diseases. Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508), Osaka, Japan Kureha Corp....
BioCentury | Oct 15, 2012
Clinical News

Kremezin: Phase III data

...initiation of dialysis, kidney transplantation or doubling of serum creatinine levels vs. placebo. Mitsubishi and Kureha...
...in San Diego in November. Mitsubishi has global rights to develop AST-120 for CKD from Kureha...
...from Kureha for liver and gastrointestinal diseases. Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508), Osaka, Japan Kureha Corp....
BioCentury | May 28, 2012
Clinical News

Zysa regulatory update

...where the product is in Phase II testing for non-constipating IBS. Ocera licensed Zysa from Kureha Corp....
BioCentury | May 10, 2010
Clinical News

AST-120: Phase II data

...were presented at the Digestive Disease Week meeting in New Orleans. Ocera licensed AST-120 from Kureha Corp....
BioCentury | Mar 1, 2010
Regulation

As good as it gets

...not currently enough to get approved," he said. Ocera licensed ex-Asian rights to AST-120 from Kureha Corp....
...Osaka:4568), Tokyo, Japan Harvard Medical School , Cambridge, Mass. Johns Hopkins University , Baltimore, Md. Kureha Corp....
BioCentury | Mar 1, 2010
Clinical News

AST-120: Completed Phase IIb enrollment

...grams oral AST-120 given thrice daily for up to 8 weeks. Ocera licensed AST-120 from Kureha Corp....
BioCentury | May 4, 2009
Clinical News

AST-120: Phase IIb started

...three times daily for 8 weeks in up to 150 patients. Ocera licensed AST-120 from Kureha Corp....
BioCentury | Feb 25, 2008
Finance

Ebb & Flow

...rights to AST-120 to treat GI and liver diseases. The candidate was from Japanese company Kureha...
...and Korea. In May 2006, Ocera released Phase III data from a trial run by Kureha...
BioCentury | Feb 21, 2008
Financial News

Ocera raises $35.5 million

...Ocera in-licensed the oral nanoporous microsphere agent, which absorbs toxins from the gastrointestinal tract, from Kureha...
BioCentury | Jan 14, 2008
Clinical News

AST-120 regulatory update

...tract, is in a Phase II trial to treat active pouchitis. Ocera licensed AST-120 from Kureha Corp....
Items per page:
1 - 10 of 19